France-based medical device company Median Technologies has signed a collaborative agreement with Microsoft to jointly develop cancer detection, diagnosis and monitoring methods using Big Data analytics.
Under the agreement, Median will assist Microsoft in installing its imaging biomarker phenotyping system (Ibiopsy) on the Microsoft Azure cloud computing platform.
Ibiopsy will enable the processing and analysing of medical images while determining biomarkers of disease in real time for cancer diagnosis and treatment purposes.
Median Technologies CEO Fredrik Brag said: "Extracting biomarkers of disease from medical images is at the core of the Precision Medicine effort.
"Big Data computing and analytics will allow efficient processing and analysis of imaging biomarkers which is essential for early detection of cancer and monitoring of new targeted cancer treatments.
"Our collaboration with Microsoft will allow us to deliver these solutions into routine clinical practice on a global scale on the Azure Cloud Computing platform."
The medical facilities and physicians in the US, Europe, and Asia will eventually be given access to Ibiopsy to cater to the requirements of image processing and data analytics needs created by the next generation of personalised cancer therapies and the explosive growth in medical imaging data.
Median Technologies and Microsoft will collaborate to assist medical centers in leveraging on the Azure capabilities.
The companies are also planning to develop the new predictive analytics methods based on machine learning and encryption capabilities that will be made available on Azure.